References
Livera, G. et al. Reproduction 135, 3–12 (2008).
Suh, E.K. et al. Nature 444, 624–628 (2006).
Gonfloni, S. et al. Nat. Med. 15, 1179–1185 (2009).
Ongkeko, W.M. et al. Laryngoscope 116, 1390–1396 (2006).
Leong, C.O., Vidnovic, N., DeYoung, M.P., Sgroi, D. & Ellisen, L.W. J. Clin. Invest. 117, 1370–1380 (2007).
Tuveson, D.A. et al. Oncogene 20, 5054–5058 (2001).
Krystal, G.W., Honsawek, S., Litz, J. & Buchdunger, E. Clin. Cancer Res. 6, 3319–3326 (2000).
Reynoso, D. & Trent, J.C. Curr. Opin. Oncol. 22, 330–335 (2010).
Carlsson, I.B. et al. Reproduction 131, 641–649 (2006).
Kerr, J.B. et al. Reproduction 132, 95–109 (2006).
Myers, M., Britt, K.L., Wreford, N.G., Ebling, F.J. & Kerr, J.B. Reproduction 127, 569–580 (2004).
Hutt, K.J., McLaughlin, E.A. & Holland, M.K. Mol. Hum. Reprod. 12, 61–69 (2006).
Acknowledgements
This work was supported by fellowships and grants from the National Health and Medical Research Council (NHMRC Australia; program grants 494802 and 257502, fellowships to J.K.F. (441101), K.J.H. (494836), C.L.S. (406675), A.S. (461299) and T.P.S. (575503)); the Leukemia and Lymphoma Society (Specialised Centre of Research grant 7015), the US National Cancer Institute (CA 80188 and CA 43540) and the Victorian Cancer Council Fellowship to C.L.S. (CRF10_20). We thank M. Olshansky for help with calculations. This work was made possible through Victorian State Government Operational Infrastructure Support and Australian Government NHMRC Independent Research Institutes Infrastructure Support Scheme.
Author information
Authors and Affiliations
Contributions
J.B.K. and K.J.H. performed and planned experiments, interpreted data and wrote the manuscript. M.C. helped with experiments and contributed data. T.P.S. performed statistical analysis and contributed to manuscript writing. A.S., J.K.F. and C.L.S. conceived of the study, planned experiments, interpreted data and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Tables 1–6 and Supplementary Figures 1–6 (PDF 7621 kb)
Rights and permissions
About this article
Cite this article
Kerr, J., Hutt, K., Cook, M. et al. Cisplatin-induced primordial follicle oocyte killing and loss of fertility are not prevented by imatinib. Nat Med 18, 1170–1172 (2012). https://doi.org/10.1038/nm.2889
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2889
- Springer Nature America, Inc.
This article is cited by
-
Distinct characteristics of the DNA damage response in mammalian oocytes
Experimental & Molecular Medicine (2024)
-
The Dominant Mechanism of Cyclophosphamide-Induced Damage to Ovarian Reserve: Premature Activation or Apoptosis of Primordial Follicles?
Reproductive Sciences (2024)
-
Enhanced pro-apoptosis gene signature following the activation of TAp63α in oocytes upon γ irradiation
Cell Death & Disease (2022)
-
Evaluation of mitochondria in mouse oocytes following cisplatin exposure
Journal of Ovarian Research (2021)
-
DNA repair in primordial follicle oocytes following cisplatin treatment
Journal of Assisted Reproduction and Genetics (2021)